Fundz

Kojin Therapeutics, Inc. reported raising $30.2 Million in an initial SEC Form D filing, from an offering of $60.2 Million

PRIVATEJun 09, 2021$30.2M of $60.2M raised

Amount Raised

$30.2 Million

$30.2 Million sold, per SEC Form D (first sale Jun 9, 2021)

Round Type

Venture

BostonBiotechnologyMedicalTherapeutics

Quick answer

Kojin Therapeutics, Inc. raised $30.2 Million in a funding round, dated June 9, 2021. Kojin Therapeutics, Inc. is based in Boston, Massachusetts, United States.

How much did Kojin Therapeutics, Inc. raise?
Kojin Therapeutics, Inc. raised $30.2 Million in a funding round on June 9, 2021.
What does Kojin Therapeutics, Inc. do?
Dr. Berger started in the biopharmaceutical industry in 1986 at Centocor – one of the first-generation biotech companies dedicated to pursuing the therapeutic and diagnostic applications of monoclonal antibodies – where..
Where is Kojin Therapeutics, Inc. based and how big is it?
Kojin Therapeutics, Inc. is based in Boston, Massachusetts, United States.

Source: Fundz verified event record.

Who else raised in Medical and Therapeutics around the same time

Companies in the same sectors as Kojin Therapeutics, Inc. that raised within 45 days of this round, from Fundz verified event records.

  • Pulse Biosciences, Inc. raised $50M on July 9, 2021.
  • OncoNano Medicine raised $50M (Series B) on June 17, 2021.
  • Immunome Inc. raised an undisclosed amount (Grant) on May 20, 2021.
  • MAIA Biotechnology raised $8M (Funding Round) on May 19, 2021.
  • Immunome Inc. raised $27M on May 11, 2021.
  • Kandu Health™ raised $260M on July 22, 2021.

Who to call at Kojin Therapeutics, Inc., and when

A new round usually means Kojin Therapeutics, Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Kojin Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Kojin Therapeutics, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Kojin Therapeutics, Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Kojin Therapeutics, Inc.

Location

One Marina Park Drive

Boston, Massachusetts, United States

About

Dr. Berger started in the biopharmaceutical industry in 1986 at Centocor – one of the first-generation biotech companies dedicated to pursuing the therapeutic and diagnostic applications of monoclonal antibodies – where he oversaw the company's R&D programs as executive vice president and president of research and development. Subsequent to his lengthy stint at ARIAD, he became executive chairman of Medinol, a leading worldwide medical device company dedicated to the science of cardiovascular intervention. Dr. Berger began his career in academic medicine at Yale School of Medicine and Emory School of Medicine, rising to professor with tenure. He received his M.D. from Yale School of Medicine and his B.S. from Colgate University and completed post-graduate training at Yale-New Haven Hospital. The Kojin founding team brings together leadership in chemical biology, genetics, immunology, cancer therapeutics, and drug discovery and development, and includes: Ferroptosis is a newly discovered form of programmed cell death that is biochemically and genetically differentiated from apoptosis, necrosis, and autophagy and is characterized by intra-cellular localization of iron and reactive oxygen species. This leads to iron-dependent accumulation of oxidatively damaged phospholipids within the cell membrane – a process that has been likened to a "grease fire" in the cell membrane, and which can be prevented or reversed by therapeutic interventions. Based in Boston, Massachusetts and named after the Japanese deity that tamed fire for the good of humanity, Kojin is harnessing groundbreaking discoveries in cell-state and ferroptosis biology to develop first-in-class treatments for use in patients with cancer, and cardiovascular, immunologic, and degenerative diseases. Kojin has developed a drug-discovery platform that integrates computational chemistry, structural biology, chemical biology, target-informed screening, and mechanism-driven pharmacology to discover therapeutics that specifically modulate ferroptosis. More information about Kojin can be found on its website (www.kojintx.com) and on LinkedIn and X (formerly known as Twitter).

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Kojin Therapeutics, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Kojin Therapeutics, Inc.'s next move

See what Strategic adds

Kojin Therapeutics, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.